Oct 27, 2025 10:45am EDT MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 23, 2025 8:36am EDT MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Oct 07, 2025 8:47am EDT MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
Sep 24, 2025 8:01am EDT MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
Sep 11, 2025 9:27am EDT MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Sep 05, 2025 9:03am EDT MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
Aug 27, 2025 9:01am EDT MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
Aug 13, 2025 9:01am EDT MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy